Multiple Sclerosis (MS) Market Access and Reimbursement Insights

Thelansis’s “Multiple Sclerosis (MS) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Multiple Sclerosis (MS) Overview

Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system characterized by chronic inflammation, demyelination, gliosis, and neuronal loss. Lesions occur at different times and sites, described as “disseminated in time and space.” The disease course varies, with most patients (70–80%) initially presenting with relapsing-remitting multiple sclerosis (RRMS), while 15–20% develop primary progressive multiple sclerosis (PPMS), and some may transition to secondary progressive multiple sclerosis (SPMS). Diagnosis requires evidence of at least two CNS inflammatory events, with relapses often partially or fully resolving. Current FDA-approved therapies—including fumarates such as diroximel fumarate, monoclonal antibodies like ocrelizumab, and other immunomodulators—aim to suppress inflammation and are most effective in early RRMS. Ocrelizumab remains the only FDA-approved disease-modifying therapy for PPMS, administered intravenously every six months. Advances in 2025 highlight a shift toward therapies targeting remyelination and neuroprotection, expanding treatment beyond immune suppression.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
  • Coverage on plans
  • Market access restrictions
  • Rebates and contracting
  • Factors influencing formulary access
  • HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
  • Level of awareness
  • Anticipated coverage on plans
  • Factors that would improve market access
  • Pricing, etc.
• Impact on brand use
  • Key factors driving and limiting brand use
  • Best and worst performers on market access, etc.
• Evolving environment
  • Payer expectations from emerging therapies
  • New policies and their expected impact, etc.
  • Advise to drug manufacturers and developers

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)